Menu
Innovation Observatory > Reports > Drugs > Pembrolizumab in Combination with Epacadostat for Unresectable or Metastatic Melanoma

< Back

Pembrolizumab in Combination with Epacadostat for Unresectable or Metastatic Melanoma

Drugs

Cancer and Palliative Care

February 2018


Melanoma is a cancer of the skin and can occur anywhere on the skin. Unusual moles, exposure to
sunlight and sunburn can affect the risk of having melanoma. When the cancer has spread into the
bones, the lymph nodes or glands nearby it is said to be at the advanced (metastatic) stage. Often
at this stage the cancer cannot be removed surgically (unresectable). Symptoms of metastatic
melanoma may include weight loss, loss of appetite and feeling extremely tired (fatigued).

Pembrolizumab is a type of immunotherapy. It stimulates the body’s immune system to fight
cancer cells. Pembrolizumab targets and blocks a protein called PD‐L1 on the surface of certain
immune cells called T‐cells. Blocking the PD‐L1 protein triggers the T‐cells to find and kill cancer
cells. Epacadostat is an agent that blocks an enzyme called IDO1, which is implicated in the growth
and spread of cancer cells. Pembrolizumab is administered by injection while epacadostat is
administered orally. If approved, pembrolizumab and epacadostat have the potential to prolong
survival without cancer progression in patients with metastatic or unresectable malignant
melanoma who have not been treated previously.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Download Full Article



Load More Related Posts
Get Alerts